July 24, 2025 — 09:15 am EDT\n\n Written by Zacks Equity Research for <a> Zacks-&gt; </a>\n\nIn its upcoming report, Astrazeneca (AZN) is predicted by Wall Street analysts to post quarterly earnings of $1.09 per share, reflecting an increase of 10.1% compared to the same period last year. Revenues are forecasted to be $14.03 billion, representing a year-over-year increase of 8.4%.\n\nOver the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.\n\nBefore a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.\n\nWhile investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.\n\nThat said, let's delve into the average estimates of some Astrazeneca metrics that Wall Street analysts commonly model and monitor.\n\nAccording to the collective judgment of analysts, 'BioPharmaceuticals- R&amp;I- Symbicort- World' should come in at $725.73 million. The estimate suggests a change of +0.5% year over year.\n\nThe collective assessment of analysts points to an estimated 'BioPharmaceuticals- R&amp;I- Pulmicort- World' of $131.45 million. The estimate indicates a year-over-year change of -15.2%.\n\nIt is projected by analysts that the 'BioPharmaceuticals- CVRM- Crestor- World' will reach $304.96 million. The estimate indicates a year-over-year change of +4.4%.\n\nThe consensus among analysts is that 'BioPharmaceuticals- CVRM- Seloken/Toprol-XL- World' will reach $140.68 million. The estimate points to a change of -6.2% from the year-ago quarter.\n\nAnalysts predict that the 'BioPharmaceuticals- R&amp;I- Symbicort- U.S.' will reach $298.58 million. The estimate indicates a year-over-year change of -0.1%.\n\nThe average prediction of analysts places 'BioPharmaceuticals- CVRM- Crestor- U.S.' at $10.65 million. The estimate points to a change of -11.2% from the year-ago quarter.\n\nThe combined assessment of analysts suggests that 'Oncology- Zoladex- U.S.' will likely reach $5.51 million. The estimate indicates a year-over-year change of +10.1%.\n\nBased on the collective assessment of analysts, 'Oncology- Tagrisso- U.S.' should arrive at $719.97 million. The estimate indicates a change of +9.4% from the prior-year quarter.\n\nAnalysts expect 'BioPharmaceuticals- R&amp;I- Fasenra- U.S.' to come in at $286.87 million. The estimate suggests a change of +7% year over year.\n\nThe consensus estimate for 'BioPharmaceuticals- CVRM- Brilinta- U.S.' stands at $130.29 million. The estimate points to a change of -31.8% from the year-ago quarter.\n\nAnalysts forecast 'Oncology- Lynparza- U.S.' to reach $337.03 million. The estimate indicates a year-over-year change of +5.7%.\n\nAnalysts' assessment points toward 'Oncology- Imfinzi- U.S.' reaching $753.20 million. The estimate indicates a change of +21.5% from the prior-year quarter.\n\nAstrazeneca shares have witnessed a change of +4.8% in the past month, in contrast to the Zacks S&amp;P 500 composite's +5.7% move. With a Zacks Rank #3 (Hold), AZN is expected closely follow the overall market performance in the near term. You can see<a> the complete list of today's Zacks Rank #1 (Strong Buy) stocks here &gt;&gt;&gt;&gt; </a>. 

AstraZeneca's Q2 earnings preview: What to expect

AstraZeneca (AZN) is predicted to report Q2 earnings of $1.09 per share, a 10.1% increase from the same period last year, with revenues forecasted at $14.03 billion, representing an 8.4% year-over-year growth. Analysts provided detailed projections for key product lines, including Symbicort-World ($725.73M, +0.5%), Pulmicort-World ($131.45M, -15.2%), and Tagrisso-U.S. ($719.97M, +9.4%). The stock has risen 4.8% in the past month, compared to the S&P 500's 5.7% gain, with a Zacks Rank #3 (Hold) indicating cautious optimism.